TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02707263
Drug: intravenous continuous infusion of heparin (IV UFH)
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02707263
Drug: Subcutaneous Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02978599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily for 5 days
Study: NCT03592082
Drug: standard antibiotic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic therapy administered per standard protocol
Study: NCT03445949
Drug: 6 months treatment with a single antiplatelet agent
Normalized name: Detoxifying agents for antineoplastic treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuing single antiplatelet agent up until 6 months
Study: NCT03586570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets matching aprocitentan tablets
Study: NCT02703337
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (SC)
Study: NCT01039103
Drug: PEG-liposomal prednisolone sodium phosphate
Normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone phosphate (DB14631)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
Study: NCT02152917
Drug: Floseal®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03113500
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03113500
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03113500
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00746512
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone placebo tablets once daily for 15 days.
Study: NCT00746512
Drug: Placebo Over-Encapsulated Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
Study: NCT01449799
Drug: GSK961081 800 microgram dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers
Study: NCT02207426
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01453296
Drug: GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW642444 25 μg; Novel dry powder inhaler
Study: NCT01453296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo; Novel dry powder inhaler
Study: NCT02894268
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 100g po bid
Study: NCT02894268
Drug: Sensitivity antibiotics
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.
Study: NCT01085006
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranexamic acid in cases, normal saline in controls
Study: NCT02182388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01763008
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Doripenem will be administered as per the recommended dose, ie, 500 mg, intravenously (ie, in the vein), for every 8 hours. Duration of treatment with doripenem: for nosocomial pneumonia including ventilator-associated pneumonia patients: 7 to 14 days; for complicated intra-abdominal infection patients: 5 to 14 days; for complicated urinary tract infection, including pyelonephritis (bacterial infection of the kidneys) patients: 10 days.
Study: NCT04154813
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine was increased from 20mg/d to the target dose (60mg/d) or below the maximum tolerable dose within 2 weeks.
Study: NCT03901352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets for oral administration
Study: NCT02641561
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is commonly used to reduce inflammation caused by gout, osteoarthritis and rheumatoid arthritis. It acts by blocking the cyclo-oxygenase 1 and 2 (COX) receptors. It has also been implicated to prevent post-ERCP pancreatitis
Study: NCT01703481
Drug: JNJ-42756493: Part 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).
Study: NCT01703481
Drug: JNJ-42756493: Part 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).
Study: NCT01595399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: an equivalent volume of normal saline to atropine IV
Study: NCT00762073
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension matching budesonide
Study: NCT01703481
Drug: JNJ-42756493: Part 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.
Study: NCT01703481
Drug: JNJ-42756493: Part 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
Study: NCT02641561
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard IVF would include 0.9% normal saline (NS) solution used during all endoscopic procedures. 0.9% NS includes equal parts sodium and chloride.
Study: NCT00595946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mcg capsules twice daily (BID)
Study: NCT02325739
Drug: FGF401
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF401 is a FGFR4 inhibitor.
Study: NCT02317796
Drug: MLR-1023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
Study: NCT02334046
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
Study: NCT02334046
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
Study: NCT02641561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo would be a suppository 50 mg x 2
Study: NCT03114540
Drug: GBT440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03079102
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An endogenous gaseous signaling molecule which stimulates soluble guanylate cyclase and may act via S-nitrosation, nitrite/nitrate or nitrated fatty acid formation.
Study: NCT02206789
Drug: Prednisolone acetate1%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
Study: NCT04203862
Drug: NPC-22
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of low dose NPC-22
Study: NCT04203862
Drug: NPC-22
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of low/middle dose NPC-22
Study: NCT04203862
Drug: NPC-22
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of middle dose NPC-22
Study: NCT04203862
Drug: NPC-22
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of middle/high dose NPC-22
Study: NCT04203862
Drug: NPC-22
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of high dose NPC-22
Study: NCT03096457
Drug: Paromomycin Sulfate
Normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical application 2 times a day during 20 days
Study: NCT03865550
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02182076
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of BIBF 1120 ES soft gelatine capsules
Study: NCT02871869
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
Study: NCT00003013
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003013
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003013
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003013
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003013
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02871869
Drug: Cinobufacini Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities
Study: NCT02057549
Drug: Conventional Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
Study: NCT04867980
Drug: ACP-196
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of 100 mg ACP-196 (1 x 100 mg capsule) on Day 1 (Treatment A) and 400 mg ACP-196 (4 x 100 mg capsules) on Day 1 (Treatment B) according to the randomization scheme.
Study: NCT04867980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of ACP-196 matching placebo (4 x 100 mg matching placebo capsules) and moxifloxacin matching placebo (1 x 400 mg matching placebo tablet) on Day 1 (Treatment D) according to the randomization scheme.
Study: NCT01257061
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion
Study: NCT01257061
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion
Study: NCT02181075
Drug: ThermoDox® (LTLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThermoDox® (LTLD) infusion at a dose of 50mg/m2 whilst under general anaesthetic during intervention (Day 1)
Study: NCT01235741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
Study: NCT03206229
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
Study: NCT01017380
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib 400 mg 1 cap before surgery
Study: NCT01017380
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg 1 tab before surgery
Study: NCT02365701
Drug: Motilitone 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks
Study: NCT02365701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
Study: NCT01047605
Drug: Neurapas balance
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 tablets single dose
Study: NCT01047605
Drug: Pascoflair 425 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets , single dose
Study: NCT01047605
Drug: P-Tabletten weiß
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets, single dose
Study: NCT00611403
Drug: Artificial Tears REFRESH ENDURA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: REFRESH ENDURA® administered twice daily in each eye for 6 months following LASIK surgery
Study: NCT01745822
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
Study: NCT00543959
Drug: MK0533
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.
Study: NCT00543959
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.
Study: NCT01077921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
Study: NCT00271713
Drug: ibandronate, calcium and vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1: 150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily or
Study: NCT00271713
Drug: placebo,calcium and vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2: placebo monthly plus 500mg calcium and 800 UI vitamin D daily
Study: NCT00847509
Drug: [F-18]FLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: The individual doses of \[F-18\]FLT contain a maximum of 10 mCi. The single IP dose is administered to the study subject approximately 30 to 60 minutes prior to the start of PET imaging.
Study: NCT01089517
Drug: E10030 plus Lucentis
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a month intravitreal injection
Study: NCT04631276
Drug: TS-091
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received single-dose of 0.1, 0.2, 0.4, 1, 5, 12.5 and 25 mg of TS-091 (tablets or drug substance powder)
Study: NCT02300194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of a placebo hydrogel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
Study: NCT02653417
Drug: RAD1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD1901
Study: NCT01635127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constituent of canakinumab
Study: NCT02600819
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg FDC tablets administered orally once daily
Study: NCT02600819
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/200/25 mg FDC tablets administered orally once daily
Study: NCT02736890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive subcutaneous placebo injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
Study: NCT04277923
Drug: Lipofundin
Approvals — FDA: no, EMA: no, PMDA: no
Description: the lipid of all-in-one is less than 4g/kg.d
Study: NCT02356159
Drug: Conditioning chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine:30 mg/m2 per day IV infusion over 30 minutes, daily On days -6, -5, -4, and -3; Cyclophosphamide:1200 mg/m2 per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m2 per day IV infusion, Daily on days 6, -5,-4, and -3 Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3; Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3
Study: NCT00676715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to ocrelizumab administered as IV infision in Cycle 1 Day 1.
Study: NCT01369836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of matched placebo.
Study: NCT00991211
Drug: Standard chemotherapy CHOP + Ritiximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
Study: NCT00499616
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00499616
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03336437
Drug: Estradiol vaginal ring
Normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol 2mg vaginal ring
Study: NCT02901184
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with Spironolactone tablets on top of standard care
Study: NCT03847506
Drug: Ezetimibe/Rosuvastatin
Normalized name: EZETIMIBE/ROSUVASTATIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Candesartan cilexetil 8 mg placebo
Study: NCT00942994
Drug: Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)~HCTZ capsule (12.5 mg, 25mg)
Study: NCT00429728
Drug: GW876008
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00865540
Drug: prednisolone acetate 1%
Normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop every 8h two days before surgery
Study: NCT00865540
Drug: ketorolac tromethamine 0.4%
Normalized name: KETOROLAC TROMETHAMINE 0.4% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop every 8h two days before surgery
Study: NCT00865540
Drug: nepafenac 0.1%
Normalized name: NEPAFENAC 0.1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop every 8h two days before surgery
Study: NCT03052400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02314637
Drug: Teneligliptin + Sulfonylurea
Normalized name: sulfanilylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teneligliptin for 52 weeks in combination with sulfonylurea
Study: NCT04126278
Drug: Barbotage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as per standard of care
Study: NCT01697514
Drug: LY2940680
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule administered orally.
Study: NCT01697514
Drug: LY2940680
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder administered orally (may be sprinkled on soft food).
Study: NCT02230670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02592057
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF tablets administered orally once daily based on approved prescribing information
Study: NCT01713101
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01396447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied in capsules.
Study: NCT03493217
Drug: ICP-022
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug product is a white, round, uncoated tablet.
Study: NCT03002025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo to JNJ-64304500 as SC injection.
Study: NCT00861705
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00861705
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03081962
Drug: Bundle
Normalized name: Refill Bundle 7 Large Office KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antibiotic intraperitoneal irrigation with gentamicin and clindamycin solution, use of Triclosan-impregnated sutures and mupirocin application over the skin staples.